Abstract
Successful adoptive chimeric antigen receptor (CAR) T-cell therapies against hematological malignancies require CAR-T expansion and durable persistence following infusion. Balancing increased CAR-T potency with safety, including severe cytokine-release syndrome (sCRS) and neurotoxicity, warrants inclusion of safety mechanisms to control in vivo CAR-T activity. Here, we describe a novel CAR-T cell platform that utilizes expression of the toll-like receptor (TLR) adaptor molecule, MyD88, and tumor-necrosis factor family member, CD40 (MC), tethered to the CAR molecule through an intentionally inefficient 2A linker system, providing a constitutive signal that drives CAR-T survival, proliferation, and antitumor activity against CD19+ and CD123+ hematological cancers. Robust activity of MC-enhanced CAR-T cells was associated with cachexia in animal models that corresponded with high levels of human cytokine production. However, toxicity could be successfully resolved by using the inducible caspase-9 (iC9) safety switch to reduce serum cytokines, by administration of a neutralizing antibody against TNF-α, or by selecting "low" cytokine-producing CD8+ T cells, without loss of antitumor activity. Interestingly, high basal activity was e...Continue Reading
References
Jan 25, 2005·Nature Medicine·Brent A HanksDavid M Spencer
Feb 25, 2005·Blood·Karin C StraathofCliona M Rooney
Aug 2, 2007·Journal of Immunotherapy·Xing DuIra Pastan
Apr 23, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael C MiloneCarl H June
Jul 14, 2009·The Journal of Biological Chemistry·Precious G MotshweneNicholas J Gay
May 21, 2010·Nature·Su-Chang LinHao Wu
Jul 30, 2010·Blood·James N KochenderferSteven A Rosenberg
Sep 16, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jiali SunCliona M Rooney
Mar 9, 2011·The Journal of Clinical Investigation·Priyadharshini NarayananDavid M Spencer
Apr 14, 2011·Cancer Research·James C LeeRenier Brentjens
Sep 14, 2013·Blood·Armen MardirosStephen J Forman
Jun 28, 2014·Blood·Brian PhilipMartin Pule
Jan 21, 2015·Cancer Immunology Research·Matthew J FrigaultCarl H June
Jan 27, 2015·MAbs·Jake ChngYuansheng Yang
May 6, 2015·Nature Medicine·Adrienne H LongCrystal L Mackall
May 16, 2015·Blood·Xiaoou ZhouMalcolm K Brenner
Feb 12, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Iulia DiaconuBarbara Savoldo
Jul 13, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Aaron E FosterDavid M Spencer
Aug 13, 2017·Cancer Discovery·Melinda MataStephen Gottschalk
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Oct 6, 2017·Cell Reports·Diogo Gomes-SilvaMaksim Mamonkin
Dec 7, 2017·Proceedings of the National Academy of Sciences of the United States of America·Li WangHao Wu
Dec 9, 2017·Human Gene Therapy·Andrew HofacreAmy H Lin
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
May 29, 2018·Nature Medicine·Theodoros GiavridisMichel Sadelain
May 29, 2018·Nature Medicine·Margherita NorelliAttilio Bondanza
Jul 5, 2018·The New England Journal of Medicine·Carl H June, Michel Sadelain
Aug 5, 2018·The Journal of Biological Chemistry·Dominic De NardoSeth L Masters
Citations
Sep 25, 2019·Cancers·Ugo TestaGermana Castelli
May 25, 2020·Leukemia·Xinghuo LiRenier J Brentjens
May 27, 2020·Cellular & Molecular Immunology·Ling WuNicholas R J Gascoigne
Oct 14, 2020·Medical Oncology·Mohadese Hashem BoroojerdiPooria Safarzadeh Kozani
Nov 6, 2020·JCI Insight·Brooke PrinzingStephen Gottschalk
Dec 8, 2020·Frontiers in Immunology·Qiang DaiXuanming Yang
Nov 2, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark A SellmyerMichael D Farwell
Jul 25, 2020·Advanced Drug Delivery Reviews·Dennis HuangNicholas A Peppas
Dec 31, 2020·Scandinavian Journal of Immunology·Julian J Freen-van Heeren
Feb 9, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiaomei WangJ Henri Bayle
Feb 29, 2020·Current Opinion in Biotechnology·Evripidis LanitisMelita Irving
Dec 10, 2020·Experimental Hematology & Oncology·Hao ZhangHe Huang
Apr 4, 2021·Cancers·Mark Gurney, Michael O'Dwyer
Apr 8, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Salvatore Fiorenza, Cameron J Turtle
Apr 20, 2021·Frontiers in Oncology·Pooria Safarzadeh KozaniShahryar Khoshtinat Nikkhoi
May 4, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jakrawadee JulamaneeHitoshi Kiyoi
May 27, 2021·Expert Opinion on Drug Discovery·Caroline M Hull, John Maher
May 20, 2021·Journal of Immunotherapy·Ofir Levin-PiaedaGideon Gross
May 28, 2021·Biologics : Targets & Therapy·Maya GloverJohn Maher
Jun 15, 2021·Journal of Immunology Research·Saghar PahlavanneshanMohsen Basiri
Aug 19, 2021·Human Gene Therapy·Hinrich Abken
Sep 27, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jessica WagnerStephen Gottschalk
Aug 1, 2020·Cancer Cell·Mihe HongYvonne Y Chen
Nov 21, 2021·Journal for Immunotherapy of Cancer·Yasmin NouriRachel Perret